PILSICAINIDE
PILSICAINIDE Basic information
- Product Name:
- PILSICAINIDE
- Synonyms:
-
- PILSICAINIDE
- PILSICAININIDE
- PILSICAINIDE(FORRESEARCHONLY)
- N-(2，6-Dimethylphenyl)tetrahydro-1H-pyrrolizine-7α(5H)-acetamide
- SUN-1165
- Sunrhythm
- N-(2,6-Dimethylphenyl)-2,3,6,7-tetrahydro-1H-pyrrolizine-7a(5H)-acetamide
- N-(2,6-Dimethylphenyl)tetrahydro-1H-pyrrolizine-7a(5H)-acetamide
- CAS:
- 88069-67-4
- MF:
- C17H24N2O
- MW:
- 272.39
- Mol File:
- 88069-67-4.mol
PILSICAINIDE Chemical Properties
- storage temp.
- Sealed in dry,2-8°C
PILSICAINIDE Usage And Synthesis
Chemical Properties
Pilsicainide: C17H24N2O?HCl?1/2H20. [88069-49-2]. It is obtained from the crystallization of ethanol-diethyl ether. Odorless, bitter taste, melting point 212 ~ 214℃. It is highly soluble in glacial acetic acid and soluble in methanol, ethanol or water.
Uses
Pilsicainide is a class IC antiarrhythmic drug, suitable for the treatment of patients with ventricular tachycardia ineffective or intolerable to other antiarrhythmic drugs.
Definition
ChEBI: Pilsicainide is a secondary carboxamide resulting from the formal condensation of the amino group of 2,6-dimethylaniline with the carboxy group of (tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetic acid. It is a sodium channel blocker which is used as an antiarrhythmic drug for the management of atrial tachyarrhythmias in Japan. It has a role as an anti-arrhythmia drug and a sodium channel blocker. It is a secondary carboxamide and an organic heterobicyclic compound.
Synthesis
Pilsicainide was obtained from tetrahydrodithickened pyrrole ethyl acetate and 2, 6-dimethylaniline heated and condensed in dioxane at 100℃ under the action of sodium hydride. It is also possible to hydrolyze tetrahydrodithickened pyrrole ethyl acetate and chlorinate it to tetrahydrodithickened pyrrole acetyl chloride, which is then condensed with 2, 6-dimethylaniline.
in vivo
Pilsicainide (SUN 1165 free acid; 2 mg/kg; i.v.; once) decreases the conduction velocity in T4-treated rat atrium by decreasing the Max dV/dt and net inward current[1].
| Animal Model: | Male Sprague-Dawley (SD) rats weighing from 200 to 220 g, with levo-thyroxine (T4) treatment[1] |
| Dosage: | 2 mg/kg |
| Administration: | Bolus injection into right external carotid vein within 2 minutes, once |
| Result: | Elongated the QT interval at 15 and 60 minutes after administration. Shortened P wave and QRS complex durations. Markedly decreased action potential amplitudes (APA) and Max dV/dt, and significantly lengthened the action potential durations. |
PILSICAINIDE Preparation Products And Raw materials
Raw materials
PILSICAINIDESupplier
- Tel
- 1-(800)-881-8210
- inquiries@lgmpharma.com
- Tel
- 0571-82693216
- info@yuhaochemical.com
- Tel
- 010-56205725
- waley188@sohu.com
- Tel
- 0411-88165855
- sales@wdspharma.com
- Tel
- sales@njromanme.com